Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGEN NYSE:EBS NASDAQ:LXRX NASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.26-0.8%$5.21$1.38▼$7.34$135.41M1.44795,783 shs156,721 shsEBSEmergent Biosolutions$7.69+0.8%$7.56$4.02▼$12.73$410.26M2.041.24 million shs392,511 shsLXRXLexicon Pharmaceuticals$1.08+0.5%$1.10$0.28▼$2.18$390.66M1.268.18 million shs1.18 million shsXOMAXOMA Royalty$34.99-1.2%$28.68$18.35▼$36.32$423.03M0.9944,913 shs17,868 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus+0.70%+0.94%-18.90%-27.90%-11.55%EBSEmergent Biosolutions-3.06%-9.40%+24.67%+14.53%+2.91%LXRXLexicon Pharmaceuticals-0.93%-6.96%+1.90%+38.96%-34.36%XOMAXOMA Royalty+1.55%+8.26%+24.47%+40.20%+24.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.26-0.8%$5.21$1.38▼$7.34$135.41M1.44795,783 shs156,721 shsEBSEmergent Biosolutions$7.69+0.8%$7.56$4.02▼$12.73$410.26M2.041.24 million shs392,511 shsLXRXLexicon Pharmaceuticals$1.08+0.5%$1.10$0.28▼$2.18$390.66M1.268.18 million shs1.18 million shsXOMAXOMA Royalty$34.99-1.2%$28.68$18.35▼$36.32$423.03M0.9944,913 shs17,868 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus+0.70%+0.94%-18.90%-27.90%-11.55%EBSEmergent Biosolutions-3.06%-9.40%+24.67%+14.53%+2.91%LXRXLexicon Pharmaceuticals-0.93%-6.96%+1.90%+38.96%-34.36%XOMAXOMA Royalty+1.55%+8.26%+24.47%+40.20%+24.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.50Moderate Buy$14.50240.78% UpsideEBSEmergent Biosolutions 3.00Buy$14.3386.37% UpsideLXRXLexicon Pharmaceuticals 2.50Moderate Buy$3.23200.00% UpsideXOMAXOMA Royalty 2.67Moderate Buy$69.5098.63% UpsideCurrent Analyst Ratings BreakdownLatest AGEN, EBS, LXRX, and XOMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025EBSEmergent BiosolutionsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.009/2/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/28/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.008/12/2025AGENAgenusZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/12/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/7/2025LXRXLexicon PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.20 ➝ $1.906/24/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$103.46M1.31N/AN/A($13.06) per share-0.33EBSEmergent Biosolutions$1.04B0.39$1.89 per share4.08$8.91 per share0.86LXRXLexicon Pharmaceuticals$31.08M12.57N/AN/A$0.40 per share2.69XOMAXOMA Royalty$28.49M14.85N/AN/A$6.95 per share5.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$227.21M-$7.15N/AN/AN/A-167.52%N/A-81.04%11/11/2025 (Estimated)EBSEmergent Biosolutions-$190.60M$2.453.143.72N/A16.38%24.63%8.97%11/5/2025 (Estimated)LXRXLexicon Pharmaceuticals-$200.40M-$0.33N/AN/AN/A-206.43%-83.63%-42.22%11/11/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.55N/AN/AN/A-27.57%2.63%0.97%11/6/2025 (Estimated)Latest AGEN, EBS, LXRX, and XOMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025XOMAXOMA Royalty-$0.12$0.48+$0.60$0.44$9.39 million$13.13 million8/11/2025Q2 2025AGENAgenus-$0.78-$1.00-$0.22-$1.00$49.71 million$25.70 million8/6/2025Q2 2025EBSEmergent Biosolutions-$0.26$0.16+$0.42-$0.22$148.55 million$140.90 million8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.08$0.01+$0.09$0.01$4.87 million$28.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/AEBSEmergent BiosolutionsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.060.06EBSEmergent Biosolutions1.255.663.00LXRXLexicon Pharmaceuticals0.434.164.16XOMAXOMA Royalty1.414.884.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%EBSEmergent Biosolutions78.40%LXRXLexicon Pharmaceuticals74.70%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%EBSEmergent Biosolutions1.20%LXRXLexicon Pharmaceuticals13.90%XOMAXOMA Royalty9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44031.86 million30.11 millionOptionableEBSEmergent Biosolutions2,42053.35 million52.71 millionOptionableLXRXLexicon Pharmaceuticals140363.40 million312.89 millionOptionableXOMAXOMA Royalty1012.09 million10.99 millionOptionableAGEN, EBS, LXRX, and XOMA HeadlinesRecent News About These CompaniesXOMA Royalty Corporation $XOMA Shares Sold by BVF Inc. ILSeptember 5 at 7:56 AM | marketbeat.comWall Street Analysts Predict an 86.05% Upside in XOMA Royalty (XOMA): Here's What You Should KnowSeptember 3 at 10:56 AM | zacks.comXOMA Royalty Corporation Executives to Present Company Update at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3 at 7:50 AM | quiverquant.comQXOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3 at 7:30 AM | globenewswire.comHere's Why XOMA Royalty (XOMA) Is a Great 'Buy the Bottom' Stock NowSeptember 1, 2025 | zacks.comQ3 EPS Estimates for XOMA Royalty Lifted by HC WainwrightAugust 26, 2025 | marketbeat.comHC Wainwright Predicts Stronger Earnings for XOMA RoyaltyAugust 24, 2025 | marketbeat.comXoma’s Strategic Acquisitions and Innovative Financial Strategies Drive Buy RatingAugust 22, 2025 | tipranks.comMural Oncology and XOMA Royalty Corporation Announce Definitive Agreement for Acquisition of Mural OncologyAugust 20, 2025 | quiverquant.comQMural Oncology to be acquired by XOMA unit for up to $2.24/share in cashAugust 20, 2025 | seekingalpha.comMural Oncology Enters Definitive Agreement for Acquisition by XOMA Royalty Corporation in Cash Deal Valued at Approximately $36.2 MillionAugust 20, 2025 | quiverquant.comQMural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per ShareAugust 20, 2025 | globenewswire.comQ3 EPS Estimates for XOMA Royalty Reduced by Leerink PartnrsAugust 19, 2025 | marketbeat.comHow Much Upside is Left in XOMA Royalty (XOMA)? Wall Street Analysts Think 106.15%August 18, 2025 | zacks.comLeerink Partnrs Raises Earnings Estimates for XOMA RoyaltyAugust 17, 2025 | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Rating Increased to Hold at Zacks ResearchAugust 17, 2025 | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Releases Earnings Results, Beats Estimates By $0.60 EPSAugust 16, 2025 | marketbeat.comXOMA Royalty Corporation Beat Analyst Profit Forecasts, And Analysts Have New EstimatesAugust 16, 2025 | finance.yahoo.comLAVA Therapeutics Announces Acquisition by XOMA CorporationAugust 14, 2025 | tipranks.comXoma Corp. Reports Strong Earnings Growth in 2025August 14, 2025 | msn.comLAVA Therapeutics Enters Agreement to Be Acquired by XOMA Royalty Corporation and Announces Discontinuation of LAVA-1266 DevelopmentAugust 13, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Big Rallies Brewing? 3 Analyst Favorites to Watch CloselyBy Nathan Reiff | August 18, 2025AGEN, EBS, LXRX, and XOMA Company DescriptionsAgenus NASDAQ:AGEN$4.26 -0.04 (-0.82%) As of 01:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Emergent Biosolutions NYSE:EBS$7.69 +0.06 (+0.80%) As of 01:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Lexicon Pharmaceuticals NASDAQ:LXRX$1.08 +0.01 (+0.47%) As of 01:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.XOMA Royalty NASDAQ:XOMA$34.99 -0.41 (-1.16%) As of 01:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
